Loading…

Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders

The gastrin-releasing peptide receptor (GRPR) has been implicated in central nervous system (CNS) diseases, including neurodevelopmental disorders associated with autism. In the present study we examined the effects of GRPR blockade during the neonatal period on behavioral measures relevant to anima...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2007-03, Vol.52 (3), p.724-732
Main Authors: Presti-Torres, J., de Lima, M.N., Scalco, F.S., Caldana, F., Garcia, V.A., Guimarães, M.R., Schwartsmann, G., Roesler, Rafael, Schröder, Nadja
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The gastrin-releasing peptide receptor (GRPR) has been implicated in central nervous system (CNS) diseases, including neurodevelopmental disorders associated with autism. In the present study we examined the effects of GRPR blockade during the neonatal period on behavioral measures relevant to animal models of neurodevelopmental disorders. Male Wistar rats were given an intraperitoneal (i.p.) injection of either saline (SAL) or the GRPR antagonist [D-Tpi 6, Leu 13 psi(CH 2NH)-Leu 14] bombesin (6–14) (RC-3095; 1 or 10 mg/kg) twice daily for 10 days from postnatal days (PN) 1 to 10. Animals treated with RC-3095 showed pronounced deficits in social interaction when tested at PN 30–35 and impaired 24-h retention of memory for both novel object recognition (NOR) and inhibitory avoidance (IA) tasks tested at PN 60–71. Neither short-term memory tested 1.5 h posttraining nor open field behavior were affected by neonatal GRPR blockade. The implications of the findings for animal models of neurodevelopmental disorders are discussed.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2006.09.020